Yvonne Saenger, MD, from Columbia University, gives a rundown of the immunotherapy options for treating melanoma.
Yvonne Saenger, MD, Director of Melanoma Immunotherapy at Columbia University, talks about the immunotherapy agents currently available for melanoma.
Along with ipulimimab, pembrolizimab and nivolumab prolonging survival in patients with melanoma, she discusses the oncolytic virus, a novel therapy using a herpes virus that attacks tumor cells preferentially.
Ridad and McKaig Discuss Oncology Nurse Perceptions on Medical Cannabis
Improvements in Health Systems Model Reduces Disparities in Leukemia Survival in Low-Income Countries
Telephone and Web-Based Program Elicits Clinically Meaningful Results in Breast Cancer Survivors
Luspatercept Elicits High Transfusion Independence Rates in Lower-Risk MDS
2 Clarke Drive
Cranbury, NJ 08512